Would You Rather?: Goldman Sachs or The Mag7… And Structure Therapeutics CEO 1/15/26

Goldman Sachs surging to fresh records as earnings top estimates, while some Mag7 stocks continue to struggle against the broader market. So will the big bank keep bumping, or can the big tech trouble make a turnaround? Plus the weight loss drug wars are heating up, with focus turning to the GLP-1 pill. The latest data from one pharma company, and what the CEO sees in store for the company as competition continues to climb.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Episode metadata supplied by the publisher feed · Published Jan 15, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Would You Rather?: Goldman Sachs or The Mag7… And Structure Therapeutics CEO 1/15/26

0:00 43:38

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of CNBC's "Fast Money"?

This episode is 43 minutes long.

When was this CNBC's "Fast Money" episode published?

This episode was published on January 15, 2026.

Can I download this CNBC's "Fast Money" episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!